Long term goal north of $3.00 (End 2018- mid 2019)
List of (Possible) events to put this stock into the big leagues and big pharma
1) Flag ship product ATB 436 is now 1 clinical study away from being marketed to the public:
- Antibe was formed to develop safer meds for pain and inflammation with Hydrogen Sulfide tech
- Product ATB 436 was advanced into Phase 2 proof of concept data
- Which showed unequivocal superiority to naproxen in GI safety
- provides full validation of the GI protective properties of Antibe's H2S tech
- Full analysis will be available next quarter
- Final trial will be Phase 2 effectiveness study
- after validation and final study complete, will be ready for large pharma markets.
2) NASDEQ LISTING
3) No stock dilution for funding, under 200 Million shares OS
4) Selling subsidiary company Citagenix:
- Subsidiary company is nearly done assembling the building blocks for its growth strategy in the dental regenerative med market. Citagenix provided Antibe with valuable diversification.
HOWEVER after last PR I am led to believe they could be in the works of looking to sell this business as there main business is so close to the global market and global validation and de-risked considerably.
5) Final link; adding in global urgency regarding addictive pain killers:
Antibe's lead drug ATB-346 targets global need for safer drug options for chronic pain.
List of (Possible) events to put this stock into the big leagues and big pharma
1) Flag ship product ATB 436 is now 1 clinical study away from being marketed to the public:
- Antibe was formed to develop safer meds for pain and inflammation with Hydrogen Sulfide tech
- Product ATB 436 was advanced into Phase 2 proof of concept data
- Which showed unequivocal superiority to naproxen in GI safety
- provides full validation of the GI protective properties of Antibe's H2S tech
- Full analysis will be available next quarter
- Final trial will be Phase 2 effectiveness study
- after validation and final study complete, will be ready for large pharma markets.
2) NASDEQ LISTING
3) No stock dilution for funding, under 200 Million shares OS
4) Selling subsidiary company Citagenix:
- Subsidiary company is nearly done assembling the building blocks for its growth strategy in the dental regenerative med market. Citagenix provided Antibe with valuable diversification.
HOWEVER after last PR I am led to believe they could be in the works of looking to sell this business as there main business is so close to the global market and global validation and de-risked considerably.
5) Final link; adding in global urgency regarding addictive pain killers:
Antibe's lead drug ATB-346 targets global need for safer drug options for chronic pain.